Skip to content
Head to head

Harrow vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: HROW · TAK

Updated 6 minutes ago

1-year performance, rebased to 100

HROW -24.5%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (88); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
HROWTAK
Snapshot
Sector----
Last price30.4121.77
Change today-5.35%+1.68%
1-year return-19.3%+57.5%
Market cap$1.14B$69.76B
52-week range25.76 – 54.8513.92 – 22.07
Valuation
P/E (TTM)-40.01311.00
P/E percentile, own 5-yr range38th100th
P/B39.091.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-0.14-0.30
Net profit (TTM)$-5.25M$-970.94M
Revenue (TTM)$303.25M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+38.6%+6.7%
Gross margin73.5%65.8%
Operating margin-2.0%14.3%
Net margin-9.4%0.9%
Free cash flow (TTM)$-38.47M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership60.7%51.3%
Insider activity (12mo)32 buy / 18 sell19 buy / 31 sell
Short interest (% of float)18.9%0.1%
Analyst consensus100% buy (7)100% buy (1)
Analyst price target$64 (+109%)$50 (+132%)
StockVane view
StockVane Quant RatingD (19)C (88)
Company
Employees37347,029
Founded20061781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.